These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 2337372)
21. Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Stoychkov JN; Schultz RM; Chirigos MA; Pavlidis NA; Goldin A Cancer Res; 1979 Aug; 39(8):3014-7. PubMed ID: 455286 [TBL] [Abstract][Full Text] [Related]
22. Interspersion of cyclophosphamide and BCG in the treatment of L1210 leukaemia and Lewis tumour. Mathé G; Halle-Pannenko O; Bourut C Eur J Cancer (1965); 1977 Oct; 13(10):1095-8. PubMed ID: 923609 [No Abstract] [Full Text] [Related]
23. [Effect of the combined use of BCG, PPD, a protein-containing preparation from allogenic tissue and cyclophosphamide in the development of methylcholanthrene-induced tumors]. Volegov AI Eksp Onkol; 1984; 6(2):63-5. PubMed ID: 6510338 [TBL] [Abstract][Full Text] [Related]
24. [Immunochemotherapy of mice S-180 ascitic tumor by combination of cyclophosphamide and BCG]. Chiou CY; Wong YH Gaoxiong Yi Xue Ke Xue Za Zhi; 1986 Mar; 2(3):164-71. PubMed ID: 3482884 [No Abstract] [Full Text] [Related]
26. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy. Adler A; Altbaum I J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275 [TBL] [Abstract][Full Text] [Related]
27. Comparative study on antitumor effect of cell-wall skeleton of Mycobacterium bovis BCG and Nocardia rubra, with reference to T-cell dependency and independency. Yanagawa E; Yasumoto K; Ohta M; Nomoto K; Azuma I; Yamamura Y Gan; 1979 Apr; 70(2):141-6. PubMed ID: 381087 [TBL] [Abstract][Full Text] [Related]
28. In vitro cytochemical and cytophysiological study of in vivo BCG-activated mouse peritoneal macrophages. Todoruţiu-Papilian C; Mulea R; Daicoviciu D Morphol Embryol (Bucur); 1985; 31(4):283-8. PubMed ID: 2934625 [TBL] [Abstract][Full Text] [Related]
29. [Macrophage activation by viable BCG in tumor-bearing mice and its relation with delayed hypersensitivity (author's transl)]. Matsuo K Fukuoka Igaku Zasshi; 1979 Aug; 70(8):465-83. PubMed ID: 488891 [No Abstract] [Full Text] [Related]
30. [An attempt to control the growth of syngeneic experimental tumors in inbred mice using Listeria factor Ei, BCG vaccine and a combination of both]. Zák M; Mára M; Jirkovský J Sb Lek; 1989 Sep; 91(8):230-7. PubMed ID: 2617123 [TBL] [Abstract][Full Text] [Related]
31. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
32. I. Tumor growth in mice with depressed capacity to mount inflammatory responses: possible role of macrophages. Nelson M; Nelson DS; Hopper KE Am J Pathol; 1981 Aug; 104(2):114-24. PubMed ID: 6789682 [TBL] [Abstract][Full Text] [Related]
33. Tumoricidal effector mechanisms of murine BCG-activated macrophages. I. Parameters of production and initial characterization of a cytolytic factor serologically related to necrosin. Klostergaard J; Foster WA; Leroux ME J Biol Response Mod; 1987 Jun; 6(3):313-30. PubMed ID: 3298554 [TBL] [Abstract][Full Text] [Related]
34. A novel rat monoclonal antibody reactive with murine tumoricidal Kupffer cells and activated peritoneal macrophages from BCG-infected mice. Someya A Immunology; 1986 Apr; 57(4):605-10. PubMed ID: 2420709 [TBL] [Abstract][Full Text] [Related]
35. Interspersion of cyclophosphamide and BCG in the treatment of L1210 leukemia and Lewis Tumor. Mathé G; Halle-Pannenko O; Bourut C Recent Results Cancer Res; 1977; (62):62-6. PubMed ID: 601338 [TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of monoclonal antibodies specific for macrophages at intermediate stages in the tumoricidal activation pathway. Paulnock DM; Lambert LE J Immunol; 1990 Jan; 144(2):765-73. PubMed ID: 2104906 [TBL] [Abstract][Full Text] [Related]
37. Induction of macrophage antitumor activity by a mycobacterial fraction. In vivo and in vitro studies. Rashid G; Gittel H; Ben-Efraim S Anticancer Res; 1994; 14(3A):1083-7. PubMed ID: 8074454 [TBL] [Abstract][Full Text] [Related]
38. Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents. Germain RN; Williams RM; Benacerraf B J Natl Cancer Inst; 1975 Mar; 54(3):709-20. PubMed ID: 1091741 [TBL] [Abstract][Full Text] [Related]
39. The role of the BCG dose and the mouse strain in the inhibition of development of neoplasms susceptible and nonsusceptible to the action of natural cytotoxic cells. Skórski T Folia Histochem Cytobiol; 1985; 23(1-2):3-10. PubMed ID: 4043437 [TBL] [Abstract][Full Text] [Related]